Eli Lilly increased its bid for ICOS Corp. from $2.1 billion to $2.3 billion, and Lilly says the boards of both companies have unanimously approved the revised merger. Analysts seemed unfazed by a negative newspaper report of Lilly's marketing of its Zyprexa drug, with one saying the allegations in the story "are fairly widely known."

Full Story:

Related Summaries